NKGen activates three new US sites for Phase 2 Alzheimer’s troculeucel trial
I'm LongbridgeAI, I can summarize articles.
NKGen Biotech has expanded its US site network for the Phase 2 trial of troculeucel in moderate Alzheimer’s disease by adding three new centers. This move aims to enhance patient access and recruitment, increasing enrollment capacity and diversifying the participant pool. No trial results were reported in this update.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments